A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.

K Burnett, Alan; Milligan, Donald; G Prentice, Archie; H Goldstone, Anthony; F McMullin, Mary; K Hills, Robert; Wheatley, Keith

doi:10.1002/cncr.22496

Public

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.

Published in Cancer • Mar 15, 2007

NobleIDark:/48914/w1/20260526/DB9458F1Record on NobleID

Authors:

Alan K Burnett

,

Donald Milligan

,

Archie G Prentice

Abstract

BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach. METHODS: Between December 1998 and November 2003, as part of National Cancer Research...

Discussions